Busulfan Fresenius Kabi 6 mg/ml concentrate for solution for infusion, Neupogen 30 MU (0,6 mg/ml) solución inyectable en jeringa precargada filgrastim, Mozobil 20 mg/ml solution for injection, Merilen
RP-L301-0119
Phase 1 small_molecule active
Quick answer
Busulfan Fresenius Kabi 6 mg/ml concentrate for solution for infusion, Neupogen 30 MU (0,6 mg/ml) solución inyectable en jeringa precargada filgrastim, Mozobil 20 mg/ml solution for injection, Merilen for Inherited metabolic disorder of the enzyme pyruvate kinase which affects the survival of red blood cells, Pyruvate Kinase Deficiency is a Phase 1 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- Inherited metabolic disorder of the enzyme pyruvate kinase which affects the survival of red blood cells, Pyruvate Kinase Deficiency
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active